Ventyx Biosciences, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Ventyx Biosciences reported reduced net losses in Q3 2025, driven by lower R&D expenses, while advancing its NLRP3 inhibitor pipeline and seeking partners for IBD programs.
Ventyx Biosciences reported a reduced net loss in Q2 2025, driven by decreased R&D expenses, and announced positive clinical data for its VTX3232 Parkinson's trial while seeking partners for other programs.
Ventyx Biosciences announces its Q1 2025 financial results, highlighting progress in its clinical-stage programs targeting autoimmune, inflammatory, and neurodegenerative diseases.
Ventyx Biosciences reports a net loss of $35.2 million for Q3 2024, alongside updates on its clinical programs and financial position.
Ventyx Biosciences reports a net loss of $70.5 million for the first half of 2024, while advancing its clinical programs for inflammatory diseases.
Ventyx Biosciences reports a net loss of $38.6 million for the first quarter of 2024, alongside positive clinical trial updates and a recent private placement raising $95.1 million.